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Abstract: Endometrial cancer is the most common gynecologic malignancy in the United States
and the sixth most common cancer in women worldwide. Fortunately, most women who develop
endometrial cancer have low-grade early-stage endometrioid carcinomas, and simple hysterectomy
is curative. Unfortunately, 15% of women with endometrial cancer will develop high-risk histologic
tumors including uterine carcinosarcoma or high-grade endometrioid, clear cell, or serous carcinomas.
These high-risk histologic tumors account for more than 50% of deaths from this disease. In this
review, we will highlight the biologic differences between low- and high-risk carcinomas with a
focus on the cell of origin, early precursor lesions including atrophic and proliferative endometrium,
and the potential role of stem cells. We will discuss treatment, including standard of care therapy,
hormonal therapy, and precision medicine-based or targeted molecular therapies. We will also discuss
the impact and need for model systems. The molecular underpinnings behind this high death to
incidence ratio are important to understand and improve outcomes.
Keywords: uterine cancer; endometrial cancer; precision medicine; treatment; hormone therapy;
stem cells; molecular features; high-risk histology
1. Introduction
Endometrial cancer is the sixth most common malignancy in women, with over 380,000 new
cases in women worldwide in 2018 [1]. In the United States, nearly 62,000 women will be diagnosed
in 2019 [2]. Unfortunately, the incidence of endometrial cancer in the United States continues to
increase [2]. Over 85% of women diagnosed with endometrial cancer will have low-grade endometrioid
carcinomas with an all-stage 5-year survival of 83% [3]. High-risk histologic carcinomas such as uterine
carcinosarcoma and high-grade endometrioid, serous, and clear cell carcinomas, are less prevalent,
but are unfortunately significantly more deadly. High-risk carcinomas account for 15% of cases, but
are responsible for up to 50% of deaths from endometrial cancer [4,5]. This review will highlight the
biologic differences between low- and high-risk carcinomas, focusing on precursor lesions, stem cells,
molecular targeted therapies, and model systems. Understanding the unique biology between the
more easily cured low-grade tumors and the significantly deadly high-risk histologic carcinomas will
impact outcomes.
2. Biologic Differences in Low- And High-Risk Histologic Endometrial Carcinomas
Historically, endometrial cancer has been categorized into two groups: type I tumors (low-grade)
or type II tumors (high-grade). This system was based on clinical, endocrine, and epidemiological
observations [6]. While this classification system has been used since the 1980s, increasing evidence
suggests this classification is imperfect [7]. Molecular and pathologic factors are more frequently
being used to classify endometrial cancer [8]. For simplicity, this review will focus on more common
Cancers 2019, 11, 1665; doi:10.3390/cancers11111665 www.mdpi.com/journal/cancers
Cancers 2019, 11, 1665 2 of 19
histopathology types, rather than the rarer. Rare tumors of the endometrium include neuroendocrine
tumors and undifferentiated tumors. Similarly rare, dedifferentiated tumors consist of low-grade
tumors adjacent to undifferentiated carcinoma. Case studies suggest these dedifferentiated tumors
are more aggressive [9–11]. In this review, we will compare two general groups: low-risk histologic
carcinomas and high-risk histologic carcinomas.
2.1. Clinical Features of Low- and High-Risk Histologic Carcinomas
Low-risk carcinomas are low-grade endometrioid carcinomas. High-risk histologic carcinomas
include carcinomas with malignant stroma such as uterine carcinosarcomas and tumors with malignant
epithelium including high-grade endometrioid, serous, and clear cell carcinomas. High-risk histologic
carcinomas are clinically very different from low-grade endometrioid carcinomas. Table 1 highlights
the general clinical features of low- and high-risk histologic endometrial carcinomas. First, high-risk
histologic carcinomas are high-grade carcinomas [12]. High tumor grade is the most significant
risk factor for subsequent death and disease recurrence [13,14]. Women with high-risk histologic
carcinomas have poor outcomes (44% 5-year all-stage survival rate). Individuals with low-grade
carcinomas have more favorable outcomes with an 83% 5-year survival rate for all stages [2,3].
Second, low-risk carcinomas are estrogen-dependent and associated with obesity. The excess estrogen
produced by adipocytes stimulates endometrial epithelial cells, leading to the precursor lesion of
endometrial hyperplasia [15]. Recent studies have highlighted the potential for counteracting the
overabundance of estrogen-effects on the uterus with a levonorgestrel-containing intrauterine system
to treat low-grade endometrial carcinoma in select women [16]. High-risk histologic carcinomas are
not typically associated with excess estrogen or obesity. High-risk histologic carcinomas develop in
a background of atrophic endometrium. Both low- and high-risk carcinomas have postmenopausal
bleeding as the key presenting symptom, facilitating diagnosis at an early stage [17].
Table 1. General clinical characteristics.
Characteristic Low-Risk Histology (85%) High-Risk Histology (15%)
Characteristic histology Low-grade endometrioid
• Uterine carcinosarcoma
• High-grade endometrioid
• High-grade clear cell
• High-grade serous
5-year survival 83% 44%
Primary therapy
• Removal of uterus and ovaries • Removal of uterus and ovaries
• Obesity may limit surgical
options • Aggressive tumor debulking• Fertility preservation with
progesterone IUD
Adjuvant therapy Usually none Chemotherapy+/-radiotherapy
Timing of presentation
• Young women (Lynch)
• Postmenopausal• Peri-menopausal
• Postmenopausal
Precursor lesion
• Proliferative endometrium • Atrophic endometrium• Endometrial hyperplasia
2.2. Health Disparities and High-Risk Histologic Carcinomas
Out of all cancers, endometrial carcinomas show the most considerable disparity due to race.
The all-stage 5-year survival for non-Hispanic black women is 62%, and for non-Hispanic white women
is 83% [2]. The incidence for both non-Hispanic white and non-Hispanic black women has remained
stable when comparing linear trends from 1997 to 2014. However, black women have had a higher
incidence of endometrial carcinoma since 2002 [18]. High-risk endometrial carcinoma has increased in
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both non-Hispanic white and black populations [18]. However, the death rate for non-Hispanic black
women remains high. Death rates for non-Hispanic black women were 8.7 per 100,000 women for the
years 2012–2016, while the death rate for non-Hispanic white women was 4.4 [19]. In addition to having
two times the death rate, non-Hispanic black women are twice as likely to be diagnosed with high-risk
disease [20]. Unfortunately, non-Hispanic black women are less likely to receive guideline-concordant
clinical care for symptoms associated with endometrial carcinoma. Regrettably, women who do not
receive guideline-concordant care are more likely to have high-risk carcinomas [21].
2.3. Pre-Cursor Lesions
Low-grade endometrioid carcinomas have a defined precursor lesion of endometrial hyperplasia.
One of the major causes for the proliferation of the endometrial epithelial cells is high levels of
estrogens, unopposed by progesterone. In women with significant obesity, high levels of estrogens
can be found due to the conversion of androgens to estrogens through the aromatase in the adipose
cells. For women with polycystic ovarian syndrome, unopposed estrogen is due to the reduced
production of progesterone from anovulatory cycles, leading to hyperproliferation [22]. Endometrial
epithelial cell hyperproliferation can lead to increased frequency of DNA damage, errors in DNA repair,
and accumulation of mutations leading to further unchecked proliferation. Complex endometrial
hyperplasia with atypia is the immediate precursor lesion for low-grade endometrioid carcinomas [15].
Reason suggests that uncontrolled proliferation may lead to additional errors in the DNA sequence
that may allow low-grade disease to progress to high-risk histologic carcinomas, although this natural
progression of the disease is not well studied.
High-risk histologic carcinomas develop within a background of atrophic endometrium.
The mechanism by which the atrophic endometrium grows into these more rare carcinomas is less
understood, and precursor lesions are not as clearly defined. Pathologic features of the precursor lesions
were recently reviewed in [15], and some serous carcinomas have serous endometrial intraepithelial
carcinoma as a precursor lesion. These lesions are confined to the surface of the endometrium without
invasion and typically have mutations in p53. Unfortunately, there is no known precursor lesion for
clear cell carcinoma, but some correlation would suggest that they may develop in endometrial polyps.
Uterine carcinosarcomas have carcinomatous and sarcomatous components. A precursor lesion has
not been identified in these components, but stem cells may play a role [15].
2.4. Stem Cells and Stem-Cell Markers
Stem cells are capable of self-renewal and the creation of mature cells through differentiation [23].
It is thought that each tissue type has a specialized stem cell. For example, hematopoietic stem cells
(HSCs) are the precursors for blood and lymphoid cells. HSCs are likely to be the best-characterized
stem cells, being studied within normal blood cell development and pathologies such as leukemias and
lymphomas [24,25]. Stem cells play a significant role in normal endometrial physiology [26]. Through
the menstrual cycle, the endometrium must undergo tissue repair, inflammation, and tissue regrowth in
preparation for embryo implantation. In women with regular menstrual cycles, endometrial stem cells
are required to supply new endometrial cells each month. Endometrial stem cells have the properties
of stem cells, categorically, clonogenicity in colony-forming assays, long-term culturing capacity,
ability to differentiate into different cell types in vitro, expression of stem cell markers, and in vivo
reconstruction of tissue. Endometrial stem cells are thought to be located near the spiral arteries
in the endometrium [26]. Endometrial stem cells have not been studied in atrophic endometrium.
However, studies suggest that mesenchymal stem cell populations change during the perimenopausal
period [27].
Intriguingly, studies have shown that bone marrow-derived stem cells can repopulate both mouse
or human endometrium [26]. In women undergoing stem cell transplant, endometrial biopsies show
donor HLA-type cells [28]. Recently, studies in mice have shown that bone marrow-derived stem cells
can repopulate the mouse uterus and allow for fertility in previously subfertile mice [29]. In these
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experiments, Hoxa11-/- mice are infertile due to defects in decidualization, a form of endometrial
stromal differentiation. Bone marrow transplant with Hoxa11+/+ bone marrow leads to stromal cells,
which decidualized. Hoxa11+/- mice are subfertile. Bone marrow transplant with Hoxa11+/+ bone
marrow rescues the subfertility [29]. Furthermore, bone marrow-derived stem cells can repopulate
disease states such as endometriosis [30,31]. Ex vivo studies suggest several factors are important in
endometrial regeneration. Recently, platelet-rich plasma has cellular effects on multiple endometrial
cell types including stromal cells, mesenchymal stem cells, and bone marrow-derived mesenchymal
stem cells. Platelet-rich plasma led to increased proliferation and migration of all cell types [32].
Repopulation of endometrial cells from bone marrow stem cells has implications for the development
of precursor lesions and disease recurrence in endometrial carcinoma after hysterectomy, although this
concept has not been studied experimentally.
In recent decades, stem cells have come into focus in the study of cancer development, progression,
and treatment via the cancer stem cell theory. The cancer stem cell theory proposes that within a
tumor, there are small populations of cells capable of the self-renewing properties seen in normal
stem cells [23,33]. However, unlike physiologically normal stem cells, cancer stems cells have a higher
mutational burden, causing them to have increased dysfunction that may be related to their highly
invasive properties. This dysfunctional signaling commonly occurs in growth signaling pathways
frequently identified in cancers (i.e., JAK/STAT, AKT, WNT, NFκB), with particular activation in cells
selected for “stemness” and may be responsible for the stem cell’s inadequate response to standard
therapies [33,34]. Since cancer stem cells are less responsive to conventional therapies than the non-stem
cell population within tumors, they are thought to survive following treatment, leading to cancer
progression or recurrence. This resistance may be related to the mutational burden they possess or
their slow cell division with increased DNA repair capability [33]. Due to their relationship to cancer
development, progression, and treatment, further study of stem cells is necessary for many types of
cancer including endometrial cancers, to better understand therapies to reduce recurrence of disease.
The expression of stem cell markers has been examined in endometrial carcinomas. Most studies
have focused on endometrioid carcinomas or uterine carcinosarcomas. Early studies with endometrioid
carcinomas showed that late-stage, high-grade disease maintained expression of epithelial stem cell
markers while early-stage disease did not. Moreover, hierarchical clustering showed that tumors with
retained expression of epithelial stem cell markers cluster most closely with late-stage disease [35].
Additionally, Musashi-1 is an RNA-binding protein that is thought to play a role in neural and epithelial
progenitor cell proliferation and division. Examination of Musashi-1 staining shows that Musashi-1
staining is high in cells within the stem cell niche of the endometrium [36]. The stem/progenitor
marker, CD133+, was determined to be a biomarker for poor prognosis tumors [37]. Isolation of cells
from primary endometrioid carcinomas revealed that CD133+ cell populations had significant stem
cell-like properties including small spheroid formation, chemotherapy resistance, clonogenicity, and the
ability to form tumors in vivo [38]. Similarly, ALDH1-high cells isolated from primary endometrioid
carcinomas exhibited similar stem-like properties [39]. Compared to work in other cancers such as
ovarian cancer, there is relatively little known about stem cell characteristics in endometrial carcinomas.
Uterine carcinosarcoma histology is composed of malignant stroma and malignant epithelium.
The cell of origin has been postulated as two different views: (1) an epithelial tumor collided with
a stromal tumor with each tumor having a distinct cell of origin, or (2) both malignant stroma and
epithelium being derived from a common stem cell precursor. The latter stem cell precursor hypothesis
is known as the combination tumor theory. Most studies suggest that uterine carcinosarcomas arise via
the combination tumor theory [40,41]. Studies have shown that CD133+ cells isolated from uterine
carcinosarcomas have properties of cancer stem cells such as differentiation into both epithelial and
stromal lineages, chemotherapy resistance, increased expression of stem cell markers including BMI1,
and in vivo transplantable tumors [42]. Studies using the CS99 cell line, which is derived from uterine
carcinosarcomas, showed that inhibition of BMI1 (BMI1 proto-oncogene, polycomb ring finger) with
the BMI1 inhibitor, PTC-028, led to increased apoptosis and decreased cell viability in vitro and delayed
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tumor growth in vivo [43]. These results suggest that targeting stem cells may be an effective treatment
for uterine carcinosarcomas.
2.5. Unique Molecular Features
Histologic classification of high-grade endometrial carcinomas can be challenging as some
carcinomas may exhibit characteristics of multiple histologic subtypes or a mixed phenotype. Detailed
histologic classification schemes were recently summarized based on discussion at the Endometrial
Cancer Workshop at the 2016 Society of Gynecologic Pathologists meeting [12]. In general, many
carcinomas can be classified based on routine hematoxylin and eosin staining and microscopic
examination. Molecular immunohistochemistry may be used when biopsy specimen does not allow
an adequate evaluation of the whole tumor (i.e., endometrial biopsy) or to determine whether
histology represents a focal area of a high-grade lesion or a pure high-grade carcinoma. The useful
immunohistochemistry analyses are listed in Table 2.
Table 2. Markers.
Marker Low-GradeEndometrioid
High-Grade
Endometrioid Clear Cell Serous
Uterine
Carcinosarcoma References
ARID1A- 8% 33–46% 13–22% 0–9% 7% [12,44–46]
Estrogen
receptor+ 84–96% 31–82% 9–21% 31–54% 8–36% [12,44,47–52]
HNF1β+ 39% 5% 67–83% 22% [44,45]
Napsin A+ 0% 0% 70–88% 8% 0% [44,47,53]
p16+ 1–7% 11–25% 45–80% 80–100% 60–78% [12,47–49,51]
p53+ 3–18% 18–69% 22–25% 44–94% 26–80% [12,46,48,50,52,54,55]
Progesterone
receptor+ 83–100% 42–68% 11–45% 6–54% 0–42% [12,44,47–49,51,52,55]
PTEN- 53% 28–75% 33% 6–100% 39% [12,48,52]
Vimentin+ 88–90% 77–92% 38–91% 27–83% 100% [12,45,51]
WT1+ 0–3% 0–27% 0–50% 33–63% 70% [12,54,56]
In terms of molecular features, TCGA (The Cancer Genome Atlas) performed a large sample size
(n = 373) integrated, genomic, and proteomic analysis of both endometrioid and serous endometrial
carcinomas. This multi-platform analysis classified carcinomas into four categories: (1) polymerase-ε
(POLE) ultramutated, with mutations in a subunit of DNA polymerase epsilon; (2) microsatellite
instability hypermutated (MSI-H); (3) copy-number low, with a lower mutational load; and (4)
copy-number high, with low mutation rates and extensive copy number variation [8]. Both high-grade
endometrioid and serous carcinomas had significant downregulation of estrogen and progesterone
receptor expression and mutations in TP53. Many low-grade endometrioid carcinomas contained
mutations in PTEN and ARID1A. Additionally, high-grade serous endometrial carcinomas shared
significant molecular features with high-grade serous ovarian cancer [8]. These results suggest that
high-grade endometrioid and serous endometrial carcinomas are molecularly unique and should be
treated differently in clinical trial analysis and design.
While the groundbreaking effort of TCGA detailed the genomic, transcriptomic, and proteomic
landscape of low- and high-grade endometrioid and high-grade serous endometrial carcinomas [8],
they did not evaluate high-grade clear cell endometrial carcinoma or uterine carcinosarcomas. Whole
exome sequencing of uterine carcinosarcomas revealed that mutations in TP53 were common (67%).
Additionally, phosphoinositide 3-kinase pathway genes were frequently mutated including PTEN,
PIK3CA, or PIK3R1. Loss of function mutations in chromatin remodeling genes including ARID1A
and ARID1B were also common [57]. Whole exome sequencing of clear cell endometrial carcinomas
similarly revealed high-frequency TP53 (39.7%), PIK3CA (23.8%), and ARID1A (15.9%) mutations.
Clear cell endometrial carcinomas contained mutational features in common with both serous and
endometrioid carcinomas [58]. Precision clinical trials that focus on unique molecular features of
individual tumors are critical to improving outcomes [59]. Table 3 highlights the frequent genetic
changes in each histology. Comprehensive analyses based on race and ethnicity are still missing.
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Table 3. Common genetic changes.
Genetic Change Low-GradeEndometrioid
High-Grade
Endometrioid Clear Cell Serous
Uterine
Carcinosarcoma Reference
ARID1A mutation 46.7% 60% 14–22% 8–10.8% 12–23.8% [15,58,60,61]
CTNNB1 mutation 23.8% 20% 0% 1–2.7% 2–4.8% [60–62]
KRAS mutation 15–24% 26.7% 0–13% 3–8.1% 9–29% [15,60,61]
PIK3CA mutation 38–56% 56.7% 14–37% 17–43% 15–41% [8,15,58,60]
PTEN mutation 67–80% 90% 0–25% 2.7–10% 18–47% [15,60,61]
TP53 mutation 10% 30% 31–50% > 85% 64–91% [8,15,60]
Microsatellite
instability 30% 56% 0–19% 0% 3.5–21% [15,58,62,63]
3. Treatment
Currently, the standard of care treatment of endometrial carcinoma consists of surgery, radiation
therapy, chemotherapy, or a combination of these [17,64]. Typically, treatment approaches are designed
by a multidisciplinary tumor board, taking into consideration the National Comprehensive Cancer
Network (NCCN) guidelines [64]. A recently published review highlights the treatment of advanced
stage endometrial cancer [65]. Included in this are innovative molecular biology techniques that
are focusing on clinically actionable changes in each woman’s carcinoma to direct therapy through
clinical trials [66]. In molecularly targeted therapy, specific molecular targets that play a critical role
in tumor progression are interrupted by medication, thus limiting harm to healthy cells. These are
considered actionable targets because the identified molecular feature (i.e., the target) in a tumor has a
specific therapy (i.e., the action) that works against tumors with that molecular feature. These genetic
changes, known as actionable targets, are typically identified by next-generation sequencing of tumors
or molecular immunohistochemistry (i.e., progesterone receptor, HER2) [67]. The Figure summarizes
some of the more promising actionable targets and their specific therapies. Moreover, epigenetic
modifying therapies hold some promise [68]. Summarized below is current information about primary
treatment, hormonal treatment, current targeted therapy, and future targeted therapies.
3.1. Primary Surgical Therapy
The principle information needed for guiding the primary treatment of endometrial cancer is the
surgical stage, grade, and histologic subtype [64]. Histologic type and grade of the tumor are first
assigned using the endometrial biopsy or dilation and curettage specimen that provided the diagnosis of
endometrial carcinoma. If the initial tissue assessment is concerning for high-risk carcinoma, then further
testing with imaging and serum CA125 is recommended to assess extrauterine involvement before
surgical staging. If instead, the initial tissue evaluation reveals low-grade endometrioid carcinoma,
then women can go directly to surgical staging without further testing [64]. Surgical resection and
staging are the mainstay of primary therapy in both high- and low-risk endometrial carcinomas.
Surgery can serve as definitive management for low-risk, early-stage disease, and guides the decision
for appropriate adjuvant treatment in later stages [64].
Comprehensive surgical staging in endometrial carcinoma includes total hysterectomy, bilateral
salpingo-oophorectomy (TH/BSO), pelvic and para-aortic lymphadenectomy, collection of peritoneal
cytology, and selective omental biopsy. If cervical involvement is suspected pre-operatively, then radical
hysterectomy should be performed in place of total hysterectomy [64]. There is somewhat competing
data in the literature about the value of full comprehensive staging, especially with regard to
lymphadenectomy, in low-risk and early-stage carcinoma. A large, multi-country randomized trial
showed that performing systematic pelvic lympadenectomy did not change overall survival or
recurrence-free survival in the setting of low-risk cancer visually confined to the uterus on operative
examination [69]. Based on this data and other supportive studies, the NCCN created criteria for when
pelvic lymphadenectomy may not be necessary including tumor size less than 2 cm, less than 50%
myometrial invasion, and well-differentiated histology [64]. In those cancers that do not meet these
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criteria, but still have low-risk histology and no operative evidence of extra-uterine disease, it may be
appropriate to perform pelvic lymphadenectomy alone, with no para-aortic dissection [64].
Unlike with low-risk early-stage endometrial carcinoma, high-risk histology and late-stage disease
have a much higher rate of metastasis and recurrence. Comprehensive surgical staging including
pelvic and para-aortic lymphadenectomy should be performed in these cases, regardless of definitive
evidence of extrauterine disease at the time of surgery [64,70]. Concerns for extra-uterine disease
or nonresectable disease leads women toward neoadjuvant systemic therapy and/or primary pelvic
radiation with reevaluation for subsequent response and surgical management [64].
3.2. Adjuvant Treatment
The indication for adjuvant therapy is based upon tumor histology, grade, and surgical
stage. The majority of endometrial carcinomas are low-grade endometrioid carcinomas and do
not require adjuvant therapy. NCCN guidelines recommend adjuvant therapy for high-risk histologic
carcinomas [64]. There is no consensus on adjuvant therapy, but options include vaginal brachytherapy,
external pelvic beam radiation therapy (EBRT), systemic chemotherapy, or a combination of these.
Even with mixed evidence, the general principle stands that higher stage, higher grade, and higher risk
histologic endometrial carcinomas are treated with more aggressive adjuvant therapy. For example,
the GOG 99 study found that for low-grade endometrioid, stage Ib disease, adjuvant vaginal
brachytherapy alone is recommended to reduce the risk of local recurrence [71].
There is no consensus on the ideal treatment for recurrent, metastatic, or high-risk disease. There are
data to support a multimodal approach [17]. Options include surgical therapy, systemic chemotherapy,
and radiotherapy [64]. Regimens may differ in type and number of chemotherapy medications, or the
order of chemotherapy and radiation. As there are no clear cut guidelines for high-risk tumors, each case
is often brought to a multidisciplinary tumor board meeting. The GOG-177 study was the first study
to report a survival advantage to early proposed treatment regimens. Paclitaxel–doxorubicin–cisplatin
was significantly superior to doxorubicin–cisplatin alone with regard to recurrence rates and overall
survival, but the triplet regimen also had substantially higher neurotoxicity [72]. Since that time,
carboplatin and paclitaxel have become the preferred regimen for systemic therapy. In the current
literature, they have similar recurrence risk and survival outcomes to previously used multi-regimen
therapies, but with much better tolerance [73,74]. The NCCN guidelines recommend carboplatin
and paclitaxel as the preferred systemic chemotherapy regimen for the treatment of high-risk or
recurrent endometrial cancer [64]. Further clinical trials are needed to understand the optimal adjuvant
chemotherapy regimen, with both treatment and tolerance endpoints. Further investigation is also
required for the evaluation of the ideal combination of chemotherapy and radiotherapy modalities for
the primary treatment of high risk, advanced, and recurrent endometrial carcinoma.
3.3. Hormone Therapy
Hormone therapy with progestins and anti-estrogens are used for a variety of purposes in the
treatment of endometrial cancer. Instead of hysterectomy, hormone therapy may be an option for select
women who wish to preserve fertility. Studies have tested oral medroxyprogesterone acetate and
levonorgestrel-containing intrauterine systems. The majority of women with low-grade endometrioid
carcinomas, who are treated with a levonorgestrel-containing intrauterine system, had disease
regression but not all [16]. Medroxyprogesterone acetate (MPA) is also used for fertility-sparing
treatment. A study conducted in Japan found a complete response rate of 90.7% in women with
early-stage low-grade endometrioid carcinoma, and 20% of women went on to have a successful
pregnancy. However, 5-year recurrence-free survival was only 33% [75]. Thus, it is critical that women
understand that fertility-sparing treatment is not a cure.
Progestin-based therapy has been widely used to treat advanced or recurrent endometrial cancer.
In a phase II trial of high-dose megestrol acetate, 24% of patients showed a response. However,
this response was not sustained, as only 31% of the responses lasted more than 18 months, and the
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median progression-free survival was only 2.5 months [76]. In a multicenter study based in Korea,
medroxyprogesterone acetate treatment combined with a levonorgestrel-containing intrauterine system
was evaluated in 35 women aged 27–40 with low-grade endometrioid endometrial cancer. After six
months of treatment, 37.1% showed a complete regression, and 25.7% showed a partial response [77].
The expression of progesterone receptor was not examined in these tumors.
Hormonal therapy may also be a viable option for women with recurrent disease, women who
require palliative care, or women who are poor surgical candidates. Assessment of steroid hormone
receptor status (i.e., progesterone and estrogen receptor) can be clinically useful in these women.
Decreased hormone efficacy in endometrial cancer has been proposed to be due to reduced PR expression
due to selective hypermethylation [78,79]. In addition to progestin therapy, anti-estrogen regimens are
an option [68]. Recently, a systemic review examined the response rate of women with advanced-stage
or recurrent endometrial carcinomas to anti-estrogen treatments [80]. Anti-estrogens included
tamoxifen, other selective estrogen receptor modulators, selective estrogen receptor downregulators,
and aromatase inhibitors. All anti-estrogens as monotherapy had a statistically significant response rate.
However, the effect of aromatase inhibitors was slight. Combination actionable target therapies such
as mTOR inhibitors with an anti-estrogen, also had a statistically significant response. Not surprising,
carcinomas which retained estrogen receptors had a higher response rate. While the response rates
were statistically significant, the response rates were less than 50%, and there were limited effects on
progression-free survival or overall survival [80]. Progestins and anti-estrogen therapies can be part of
the systemic and locally-released treatments for endometrial carcinomas.
3.4. Targeted Therapy for HER2+ Tumors
An actionable target is an identified molecular feature in a cancer that has a specific treatment
against that molecular feature. Amplification of ERBB2 (Erb-B2 receptor tyrosine kinase 2, also known
as HER2) is an actionable target. ERBB2 is an epidermal growth factor receptor whose phosphorylation
leads to the activation of proliferation and migration. Trastuzumab is a monoclonal antibody to
ERBB2 that leads to antibody-dependent cytotoxicity. Overexpression of ERBB2 in early endometrial
carcinomas is associated with disease recurrence [81]. Whole exome sequencing of clear cell endometrial
carcinomas showed 11% of tumors harbored amplification in ERBB2 [82]. Serous endometrial
carcinomas frequently have overexpression or amplification of ERBB2. Up to 53% of serous endometrial
carcinomas have overexpression of ERBB2. Furthermore, some serous tumors had areas of both low
and high HER2 expression [83,84]. As many endometrial carcinomas have this molecular feature
that has a potential adjuvant therapy, some pathologists recommend routine immunohistochemistry
staining for HER2 [83].
A case report of amplification of ERBB2 in uterine carcinosarcoma led to the treatment of a
woman with trastuzumab and complete remission of recurrent disease [85]. Another study described
the progression of disease on trastuzumab with paclitaxel in three women with HER2+ recurrent
high-risk histology tumors including two serous and one endometrioid [86]. In vitro experiments
in cells that overexpress ERBB2 showed that oncogenic mutations in PI3K resulted in resistance to
afatinib, a tyrosine kinase inhibitor that inhibits ErbB signaling [87]. A randomized trial of systemic
chemotherapy (carboplatin and paclitaxel) with trastuzumab in serous carcinomas increased median
progression-free survival from 8.0 months to 12.6 months. The experimental treatment regimen was
well tolerated and had no increase in toxicity [88]. Thus, ERBB2 remains an actionable target for
some women.
3.5. Immune Therapy for MSI-H Carcinomas
Immune checkpoint inhibitors hold significant promise for women with endometrial carcinoma.
Endometrial cancers are the most frequent cancers to have mismatch repair deficiency [89]. Furthermore,
programmed cell death-1 (PD-1) and its ligand PD-L1 are highly overexpressed in primary and
metastatic endometrial carcinomas [90]. This overexpression is associated with the microsatellite
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instability-high (MSI-H) status of tumors [91]. Without MSI testing, women with recurrent endometrial
cancer who had failed multiple lines of testing were enrolled in a study to receive pembrolizumab,
an immune checkpoint inhibitor, and lenvatinib, a VEGF receptor kinase inhibitor. The overall response
rate was 48% [92]. A clinical trial examined the response of PD-1 blockade in patients with mismatch
repair deficiency across different solid tumor types. Out of the 86 total participants, 15 participants
had endometrial cancer, and three of the 15 (20%) showed a complete response to the pembrolizumab
regimen. For the endometrial cancer patients, the objective response rate and disease control rate
were 53% and 73%, respectively. The disease control rate was defined as the percentage of individuals
who showed a complete response, partial response, or stable disease for 12 weeks or longer [89].
Thus, immune checkpoint inhibitors hold significant promise in women with endometrial carcinoma.
However, there may be a need to determine patient selection characteristics based on the molecular
features of the tumor.
3.6. Select Studies from Promising Molecular Targeted Therapies
NCCN guidelines recommend a genetic risk evaluation for all ovarian carcinomas, but those
guidelines have not extended to endometrial carcinomas. A recent study examined the prevalence
of detailed molecular characterization and the use of actionable treatments for gynecologic cancers
including both ovarian and endometrial carcinomas. This dataset included 46 women with endometrial
cancer. A majority of endometrial cancers (73%) had actionable targets identified. Low-risk tumors had
more actionable mutations. After the discovery of actionable targets, treatment plans were changed in
56% of women with endometrial cancer. Most of the targeted therapies involved hormonal therapy
(i.e., tamoxifen, letrozole, or medroxyprogesterone acetate) or mTOR inhibition (i.e., everolimus or
temsirolimus) [67]. The frequency of actionable mutations was similar to the frequency of actionable
mutations in ovarian cancer. Clinically, all ovarian cancers should have next-generation sequencing to
determine actionable mutations. Endometrial cancer guidelines do not yet recommend this technology.
However, this study highlights the fact that endometrial cancers have as many actionable targets
identified that clinically change therapy and should be studied further [67].
As many endometrial cancers harbor mutations in PTEN, mammalian target of rapamycin (mTOR)
inhibitors are a logical treatment option. The mTOR inhibitor temsirolimus has been studied in phase
II trials in women with recurrent or metastatic endometrial cancer. In the group of 20 women who had
not previously received chemotherapy, 14% showed a partial response, and 69% had stable disease.
In the group of 25 women who had previously received chemotherapy, 4% showed a partial response,
and 48% had stable disease. When compared to single-agent chemotherapeutic or hormonal agent
regiments, temsirolimus had a lower proportion (17%) of patients that exhibited disease progression [93].
Unfortunately, studies of mTOR inhibitors (i.e., everolimus, temsirolimus, or ridaforolimus) have
shown modest effects. These modest effects may be attributed to the crosstalk with the PI3K/AKT
pathway and other pathways [65]. For example, KRAS mutations lead to resistance to everolimus [94].
Positively, an in vitro study suggests that inhibition of mTOR increases sensitivity to PARP inhibitors
(i.e., olaparib, talazoparib, and BKM-120) [95].
Obesity and insulin resistance are known risk factors for endometrial cancer [17]. Insulin-like
growth factor 1 (IGF-1) may have a role in the increased rates of endometrial cancer seen in diabetic
patients. After binding of IGF-1 to its receptor IGF1-R, activation of the PI3K signaling pathway can
occur, promoting cell growth, and inhibiting apoptosis. Inhibition of the IGF1-R pathway has been
shown to have anticancer effects [96]. Metformin, conventional therapy for treating insulin resistance,
likely acts similarly to mTOR inhibitors. Metformin activates AMP-activated protein kinase (AMPK),
thereby regulating energy metabolism. AMPK is activated via phosphorylation by the kinase LKB1
and plays an active role in the regulation of the mTOR pathway [97]. Polycystic ovary syndrome
(PCOS) is a multisystem disorder with reproductive, metabolic, and cardiovascular effects. Insulin
resistance is a concern in individuals with PCOS, and reducing insulin levels has been associated with
an improvement in menstrual dysfunction and reestablishment of ovulation cycles [98]. When given to
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women with PCOS, metformin resulted in restored ovulation and improved fertility [99]. When tested
on endometrial cancer cell lines (ECC1 and Ishikawa), metformin treatment resulted in the inhibition of
cell growth, induction of apoptosis, and decreased TERT (telomerase reverse transcriptase) expression,
which is an oncogenic determinant [97]. Unfortunately, multiple ECC1 isolates have been genotyped
as Ishikawa cells [100]. Others have shown the in vitro effects of metformin on Ishikawa cells including
cell cycle arrest, apoptosis, sensitization to paclitaxel, and sensitization to progesterone [101–103].
A pooled meta-analysis of seven clinical studies showed that metformin reduced the risk of endometrial
carcinoma recurrence (odds ratio (OR) = 0.5, 95% confidence interval (CI) 0.28–0.92, p < 0.05) and
improved overall survival (hazard ratio (HR) = 0.61, 95% CI 0.48–0.77, p < 0.05). The overall survival
was further enhanced in women with diabetes (HR = 0.47, 95% CI 0.33–0.67, p < 0.05) [104]. These
are encouraging results for the use of metformin in women at high-risk for endometrial cancer as a
preventative strategy and improving patient outcomes [97,99].
The poly-ADP ribosylation of DNA repair proteins is catalyzed by the enzyme poly(ADP-ribose)
polymerase (PARP). PARP inhibitors were first designed to act against cells containing BRCA1 or BRCA2
mutations; however, clinical trials have indicated that these agents may be applicable in other cancers
as cells that are deficient in PTEN have been shown to display sensitivity to PARP inhibitors [105].
Studies of endometrioid endometrial cancer showed that PTEN-deficient cell lines were not responsive
to monotherapy of the PARP inhibitor, Olaparib. However, cell growth was inhibited in vitro when
treated with the PARP inhibitior, Olaparib, combined with PI3K inhibition by BKM120. Importantly,
this combination also showed inhibition of tumor growth in a genetically engineered mouse model of
endometrial cancer (AdCre; Ptenf/f; Lkb1f/f) [106].
ARID1A is frequently mutated in endometrial carcinomas (Table 3). Pre-clinical studies show
that EZH2 inhibitors lead to the inhibition of ARID1A-mutant cancer cell lines via spheroid size
and regression of tumors in vivo [107]. Similarly, studies in ARID1A-mutated ovarian cancer cell
lines showed that the pan histone deacetylase inhibitor, suberoylanilide hydroxamine, also leads to
decreased in vitro and in vivo tumor size [108]. Expanding beyond ARID1A to other members of the
SWI/SNF complex subunit, Januario et al. showed that SMARCA4-mutant tumors were also sensitive
to EZH2 inhibition, although no endometrial cancer cell lines were studied [109]. Furthermore, EZH2
inhibition in ARID1A-mutant cells may result in EZH2 inhibition that may be overcome by the addition
of BCL2 inhibitors [110]. Understanding the complex synthetic lethality pathways and resistance
pathways in other cancers may be useful toward treatments in similarly mutant endometrial cancers.
Mutations of epidermal growth factor receptor (EGFR) and its family are found in 43%-67% of
endometrial carcinomas [111,112]. Erlotinib is a tyrosine kinase inhibitor for EGFR that likely leads to
cell cycle arrest and angiogenesis inhibition [113]. A preclinical orthotopic mouse study showed the
antitumor effects of erlotinib on both Ishikawa and HEC1A cells with a high expression of EGFR [114].
A phase II study of erlotinib for women with recurrent or advanced endometrial cancer showed an
objective response rate of 12.5% and disease stabilization in nearly 50%. The response did not correlate
with EGFR amplification or mutation. The authors speculate that erlotinib may be targeting EGFR,
but affecting novel downstream pathways involved in PI3K signaling and progesterone resistance [113].
4. Model Systems
4.1. Mouse Models
Many genetically engineered mouse models of endometrial cancer have been created
(Supplementary Table S1). However, none of the genetically engineered mouse models of endometrial
cancer recapitulate the high-risk histologic carcinomas. Recently in Belgium, patient-derived xenograft
(PDX) models were created from uterine carcinosarcomas. Out of seven samples, only two uterine
carcinosarcomas engrafted. Importantly, tumors from these PDX models were molecularly characterized
using molecular immunohistochemistry, copy number analysis, and RNA sequencing. Uterine
carcinosarcomas maintained cytokeratin and vimentin staining in PDX when compared to the initial
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samples. Copy similarities ranged from 47.4–65.8%. A comparison of the transcriptomic profile of the
original tumor sample to PDX showed that only one of the two samples clustered with its original
tumor sample [115]. Similarly, PDX models of high-risk histologic tumors were created in China
and compared to the original tumors using molecular immunohistochemistry and RNA-sequencing
technology. Tumor samples from 18 women included ten high-grade endometrioid, six serous, one
clear cell, and one carcinosarcoma. Interestingly, tumors were implanted into hormone depleted
female mice. The clear cell carcinoma sample did not engraft, 2/6 serous carcinoma samples did not
engraft, and one high-grade endometrioid carcinoma sample did not engraft. Only six PDX models had
sufficient samples for immunophenotypic analysis. All PDX and original samples showed a similar
expression of estrogen receptor, progesterone receptor, cytokeratin, and p53. Genomic analysis was
only performed on two high-grade endometrioid samples. DNA mutation and transcriptomic changes
correlated well between the original tumor and the PDX model [116]. Thus, additional genetically
engineered mouse models of high-risk histologic carcinoma are needed. Furthermore, efforts to create
PDX models of diverse racial and ethnic backgrounds will be necessary.
4.2. In Vitro Systems
Many human endometrial cancer cell lines have been created (Supplementary Table S2).
Importantly, the CRISPR/Cas9 gene-editing tool has allowed for the development of engineered
cancer cell models. The endonuclease Cas9 makes a double-strand break at the target site. The break
can then be imperfectly repaired by the cellular mechanism non-homologous end joining, thereby
introducing a mutation or gene knockout [117]. CRISPR technology was used to show that serum
deprivation-response protein affects the expression of ALDH1 in HEC1B, HEC-108, HEC-116, and
SNG-M cells. These studies essentially represent endometrioid carcinomas [118]. In serous carcinoma
cell lines, CRISPR technology was used to introduce mutations in FBXW7, F-box, and WD repeat
domain containing 7. Both the ARK1 and ARK2 cell lines with FBXW7 mutations showed increased
sensitivity to SRC inhibitors as well as dinaciclib, a CDK2 inhibitor [119]. The generation of such
modified cell lines that genetically and phenotypically mimic cancer types allows for downstream
functional studies and the potential to advance the field of targeted cancer therapeutics.
5. Future Systems
As an innovative technology, liquid biopsy has become an important diagnostic and prognostic
test, moving in the direction of precision oncology [120,121]. This tool can detect circulating biomarkers
such as circulating tumor DNA (ctDNA) and circulating free DNA (cfDNA) to gain information on
the genetic basis of cancers, thereby diagnosing inaccessible tumors, predicting disease recurrence,
assessing drug resistance, and providing direction for personalized treatment [120,122]. Additional
advantages of the liquid biopsy include that it is minimally invasive, can provide early detection of
cancer, and only requires up to 6–10 mL of blood [121]. Assessment of liquid biopsies has proven to be
an accurate tool for cancers of the lung, prostate, and breast [123–125], but there have been few studies
in comparison to gynecological cancers [126].
However, uterine lavage has been used to study proprotein convertases (PCs). PCs have a role in
the cleavage of precursor proteins such as growth factors, hormones, and receptors, thereby activating
them. PCs are associated with tumor development, though they are also found in normal tissue
cells [127]. After assessing the expression of various PCs in the cell lines, only the upregulation of
furin was consistently observed in all of the tested cell lines, providing evidence for its association
with the development of endometrial carcinomas. Furthermore, endometrial cancer patients were
found to have significantly increased total PC activity in uterine lavage when compared to the control
patients [128,129]. This new, non-invasive technique of analyzing PC expression in uterine lavage fluid
has been proposed as a new screening technique in postmenopausal women for early detection of
endometrial cancer [127–129]. Additionally, PC inhibitors may play a future role in precision cancer
therapy [127].
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Additionally, there is ongoing research on using cervical fluid samples retrieved during routine
Papanicolaou (Pap) as the basis of a new screening tool called PapSEEK [130]. The PapSEEK test is
currently in development as an early endometrial and ovarian cancer diagnostic tool. This tool uses a
cervical cytobrush to collect epithelial cells and the DNA that has been shed from the uterine lining.
Next-generation sequencing is utilized to detect tumor DNA, potentially at a stage before cells are
even available for histologic analysis [130]. Further studies are required to determine the optimal
cytobrush. One limitation of these molecular assays is that similar mutations in benign and malignant
endometrium may affect the test’s specificity. To complicate this even more, the endometrium is
composed of both epithelial and stromal cells. Recent studies show that endometrial epithelium and
stroma contain distinct mutation profiles, even from benign endometrium from the same woman [131].
Potential oncogenic mutations found included PIK3CA, KRAS, PIK3R1, and FGFR2 in benign epithelial
endometrium from women with uterine fibroids, and ARID1A mutations in endometrial stroma from
women with endometriosis [131]. Finally, because the PapSEEK test is designed for both ovarian
and endometrial cancer, clinical next steps have not been determined. As ovarian cancer screening
algorithms have led to significant morbidity and mortality from next step diagnostic tests, these
next steps are critical for the evaluation of a screening test [132]. Importantly, making screening and
diagnosis less daunting may improve compliance with guideline-concordant care.
6. Conclusions
Despite medical developments, survival has not improved in women with endometrial cancer.
While surgery alone or in combination with systemic or radiation therapy for confined diseases can be
curative, individuals with metastatic or recurrent disease have reduced response rates to hormonal
and chemotherapeutic agents. Further research on risk factors, genetics, and medical therapies is
essential to counter the increasing death rates. In recent years, there have been widespread efforts
toward incorporating molecular testing into the clinical evaluation and for these tests to serve as
prognostic indicators. The identification of molecular aberrations, genetic mutations, and dysregulated
pathways in endometrial carcinomas will be of great significance in the development of further
immunotherapeutic and personalized therapeutic agents.
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